4/22
11:55 am
elev
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) [Seeking Alpha]
Medium
Report
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) [Seeking Alpha]
4/9
08:09 am
elev
Elevation Oncology, Inc. (NASDAQ: ELEV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Elevation Oncology, Inc. (NASDAQ: ELEV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
4/8
04:38 pm
elev
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 [Yahoo! Finance]
4/8
04:30 pm
elev
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Low
Report
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
3/7
04:42 pm
elev
Merrimack Reports Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Merrimack Reports Full Year 2023 Financial Results [Yahoo! Finance]
3/7
02:12 pm
elev
Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
Neutral
Report
Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
3/7
10:23 am
elev
Elevation Oncology, Inc. (NASDAQ: ELEV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
Medium
Report
Elevation Oncology, Inc. (NASDAQ: ELEV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
3/7
08:25 am
elev
Elevation Oncology, Inc. (NASDAQ: ELEV) had its price target raised by analysts at Wedbush from $5.00 to $8.00. They now have an "outperform" rating on the stock.
Medium
Report
Elevation Oncology, Inc. (NASDAQ: ELEV) had its price target raised by analysts at Wedbush from $5.00 to $8.00. They now have an "outperform" rating on the stock.
3/6
07:38 am
elev
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]
Medium
Report
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]
3/6
07:30 am
elev
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
Low
Report
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
3/5
05:03 pm
elev
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
3/5
04:50 pm
elev
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Low
Report
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
3/4
07:43 am
elev
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors [Yahoo! Finance]
Medium
Report
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors [Yahoo! Finance]
3/4
07:30 am
elev
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
Medium
Report
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
3/1
08:09 am
elev
Elevation Oncology, Inc. (NASDAQ: ELEV) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $7.00 price target on the stock.
High
Report
Elevation Oncology, Inc. (NASDAQ: ELEV) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $7.00 price target on the stock.
2/29
08:00 am
elev
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
High
Report
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
2/28
07:35 am
elev
Elevation Oncology to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Neutral
Report
Elevation Oncology to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/28
07:30 am
elev
Elevation Oncology to Participate in Upcoming Investor Conferences
Low
Report
Elevation Oncology to Participate in Upcoming Investor Conferences
2/22
07:44 am
elev
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan [Yahoo! Finance]
Medium
Report
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan [Yahoo! Finance]
2/22
07:30 am
elev
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
Medium
Report
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
2/20
08:11 am
elev
Elevation Oncology, Inc. (NASDAQ: ELEV) had its price target raised by analysts at HC Wainwright from $1.50 to $6.00. They now have a "buy" rating on the stock.
Low
Report
Elevation Oncology, Inc. (NASDAQ: ELEV) had its price target raised by analysts at HC Wainwright from $1.50 to $6.00. They now have a "buy" rating on the stock.